New HIV combo pill tested for rapid start in 100 patients

NCT ID NCT07357584

Not yet recruiting Disease control Sponsor: Fundación Huésped Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a once-daily pill containing doravirine, lamivudine, and tenofovir can quickly control HIV in people who have never taken HIV drugs before. One hundred newly diagnosed adults will take the pill for 48 weeks. The main goal is to see how many have undetectable virus levels at the end of the study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Doravirine/lamivudine/tenofovir disoproxil (Delstrigo) oral tablet
What this could lead to: If successful, this could show that starting this three-drug combination quickly after diagnosis helps control HIV effectively, offering a simple once-daily option for new patients.
What could go wrong: This is a phase 4 trial with only 100 participants, so results may not apply to everyone. As with any HIV treatment, side effects or drug resistance could occur, and the virus may not be fully suppressed in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Fundacion Huesped

Buenos Aires, C1202ABB, Argentina
Fundacion IDEAA -Infectologia de atencion ambulatoria

Ciudad Autonoma de Buenos Aire, Buenos Aires, C1405CKC, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.